Show simple item record

dc.contributor.authorYazdanpanah, Yazdanen_US
dc.contributor.authorPerelman, Julianen_US
dc.contributor.authorDiLorenzo, Madeline A.en_US
dc.contributor.authorAlves, Joanaen_US
dc.contributor.authorBarros, Henriqueen_US
dc.contributor.authorMateus, Céuen_US
dc.contributor.authorPereira, Joãoen_US
dc.contributor.authorMansinho, Kamalen_US
dc.contributor.authorRobine, Marionen_US
dc.contributor.authorPark, Ji-Eunen_US
dc.contributor.authorRoss, Eric L.en_US
dc.contributor.authorLosina, Elenaen_US
dc.contributor.authorWalensky, Rochelle P.en_US
dc.contributor.authorNoubary, Farzaden_US
dc.contributor.authorFreedberg, Kenneth A.en_US
dc.contributor.authorPaltiel, A. Daviden_US
dc.date.accessioned2014-03-11T10:15:47Z
dc.date.issued2013en_US
dc.identifier.citationYazdanpanah, Y., J. Perelman, M. A. DiLorenzo, J. Alves, H. Barros, C. Mateus, J. Pereira, et al. 2013. “Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness.” PLoS ONE 8 (12): e84173. doi:10.1371/journal.pone.0084173. http://dx.doi.org/10.1371/journal.pone.0084173.en
dc.identifier.issn1932-6203en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879235
dc.description.abstractObjective: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening. Design: We used Portuguese national clinical and economic data to conduct a model-based assessment. Methods: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292 cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental cost-effectiveness. Results: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months (QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of €28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for example screening annually in men who have sex with men or screening every three years in regions with higher incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively. Conclusions: One-time HIV screening in the Portuguese national population will increase survival and is cost-effective by international standards. More frequent screening in higher-risk regions and subpopulations is also justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk populations and geographic settings.en
dc.language.isoen_USen
dc.publisherPublic Library of Scienceen
dc.relation.isversionofdoi:10.1371/journal.pone.0084173en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867470/pdf/en
dash.licenseLAAen_US
dc.titleRoutine HIV Screening in Portugal: Clinical Impact and Cost-Effectivenessen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalPLoS ONEen
dash.depositing.authorLosina, Elenaen_US
dc.date.available2014-03-11T10:15:47Z
dc.identifier.doi10.1371/journal.pone.0084173*
dash.authorsorderedfalse
dash.contributor.affiliatedFreedberg, Kenneth
dash.contributor.affiliatedLosina, Elena
dash.contributor.affiliatedWalensky, Rochelle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record